BeOne Medicines AI Stock Analysis
Want to see ONC full AI Analyst Report?
BeOne Medicines (ONC) AI Stock Analysis
BeOne Medicines
(NASDAQ:ONC)
The score is driven primarily by the financial turnaround and strong cash flow profile, reinforced by a very positive earnings call with raised 2026 guidance. Technicals are supportive with price above key moving averages and positive momentum. Valuation is the main offset, with a relatively high P/E and no dividend yield provided.
BeOne Medicines (ONC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $43.95B
- Dividend Yield
- ―
- Average Volume (3M)
- 394.11K
- Price to Earnings (P/E)
- 65.9
- Beta (1Y)
- 0.70
- Revenue Growth
- 33.13%
- EPS Growth
- 1272.97%
- Country
- US
- Employees
- 12,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
BeOne Medicines Business Overview & Revenue Model
Company Description
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule...
How the Company Makes Money
BeOne Medicines makes money primarily by commercializing prescription oncology drugs and recording product revenue from sales to wholesalers, distributors, hospitals, specialty pharmacies, and other healthcare channels (depending on market structure)...
BeOne Medicines Earnings Call Summary
The call was strongly positive, characterized by 33% product revenue growth, substantially higher operating income and free cash flow, raised 2026 guidance, sustained BRUKINSA momentum, and broad progress across hematology and solid tumor programs. The main challenges were the approximately $50 million order-timing benefit, future revenue pressure from biosimilars and potential VBP inclusion, a statutory Medicare Part D headwind, a PHESGO impairment charge, a more modest pace of future margin expansion, and the delayed tacabrutideg filing. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, BeOne Medicines raised and narrowed guidance to total revenue of $6.9 billion-$7 billion, gross margin in the high 80% range, operating expenses of $4.9 billion-$5 billion, GAAP operating income of $1.2 billion-$1.3 billion, and non-GAAP operating income of $1.9 billion-$2 billion; it expects a modest net pricing benefit in the U.S. for BRUKINSA for the balance of the year, while looking ahead to 2027, it expects relatively stable net pricing and a flat to modest headwind from the increase in Medicare Part D manufacturer liability, operating expenses growth to be at least consistent with where we have been over the past several years, operating income to continue to grow meaningfully, and the pace of margin expansion to be modest as compared to 2025 and 2026; the current expectation is that the income tax valuation allowance reversal will occur in the fourth quarter and result in a material tax benefit.
BeOne Medicines Financial Statement Overview
Summary
Strong TTM turnaround: ~$6.61B revenue with very high gross margin (~88%), positive EBIT margin (~15.7%) and net margin (~10.7%). Cash generation is a standout with ~$1.79B operating cash flow and ~$1.36B free cash flow, showing solid cash conversion. Balance sheet leverage is manageable (TTM debt-to-equity ~0.22) with improved ROE (~14.3%), though prior multi-year loss/cash-burn history (2022–2024) remains an execution risk if profitability weakens.
Income Statement
78PositiveBalance Sheet
74PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.61B | 5.34B | 3.81B | 2.46B | 1.42B | 1.18B |
| Gross Profit | 5.91B | 4.67B | 3.22B | 2.08B | 1.13B | 1.01B |
| EBITDA | 1.43B | 616.77M | -361.24M | -738.16M | -1.89B | -1.39B |
| Net Income | 915.57M | 286.93M | -644.79M | -881.71M | -2.00B | -1.46B |
Balance Sheet | ||||||
| Total Assets | 9.88B | 8.19B | 5.92B | 5.81B | 6.38B | 8.54B |
| Cash, Cash Equivalents and Short-Term Investments | 5.78B | 4.55B | 2.63B | 3.17B | 4.53B | 6.62B |
| Total Debt | 1.15B | 2.00B | 1.08B | 930.18M | 596.67M | 694.64M |
| Total Liabilities | 4.06B | 3.83B | 2.59B | 2.27B | 2.00B | 2.40B |
| Stockholders Equity | 5.82B | 4.36B | 3.33B | 3.54B | 4.38B | 6.13B |
Cash Flow | ||||||
| Free Cash Flow | 1.36B | 941.74M | -669.77M | -1.75B | -1.97B | -1.61B |
| Operating Cash Flow | 1.79B | 1.13B | -140.63M | -1.16B | -1.50B | -1.30B |
| Investing Cash Flow | -214.86M | -276.15M | -548.35M | 60.00M | 1.08B | 640.66M |
| Financing Cash Flow | 331.44M | 1.06B | 193.45M | 416.48M | -18.97M | 3.64B |
BeOne Medicines Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ONC, the sentiment is Positive. The current price of 411.29 is above the 20-day moving average (MA) of 388.82, above the 50-day MA of 370.24, and above the 200-day MA of 328.15, indicating a bullish trend. The MACD of 14.04 indicates Negative momentum. The RSI at 63.69 is Neutral, neither overbought nor oversold. The STOCH value of 84.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ONC.
BeOne Medicines Risk Analysis
BeOne Medicines disclosed 93 risk factors in its most recent earnings report. BeOne Medicines reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBeOne Medicines Peers Comparison
Overall Rating
EXEL81Outperform
ONC76Outperform
INCY73Outperform
GMAB63Neutral
ZLAB49Neutral
SMMT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $16.37B | 19.59 | 45.54% | ― | 9.12% | 40.53% | |
| 76Outperform | $46.53B | 65.87 | 18.24% | ― | 33.13% | 1272.97% | |
| 73Outperform | $24.51B | 57.42 | 7.11% | ― | 24.88% | -65.67% | |
| 63Neutral | $31.10B | 43.72 | 12.26% | ― | 19.61% | -50.40% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $3.07B | -13.51 | -31.11% | ― | 0.25% | 8.33% | |
| 43Neutral | $9.45B | -10.91 | -138.81% | ― | ― | 13.96% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ONC | BeOne Medicines | 411.29 | 57.50 | 16.25% | |
| EXEL | Exelixis | 67.10 | 24.96 | 59.23% | |
| INCY | Incyte | 120.27 | 18.95 | 18.70% | |
| SMMT | Summit Therapeutics PLC | 11.82 | -4.74 | -28.62% | |
| ZLAB | Zai Lab Ltd | 23.47 | 2.97 | 14.49% | |
| GMAB | Genmab (Otc) | 51.57 | 21.00 | 68.69% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
